Webinar on Modernizing the NIH Data and Safety Monitoring Policy

To enhance efficiency and rigor, NIH intends to modernize the approach to data and safety monitoring and is committed to engaging the public in development of an updated policy. Since the 1998 NIH Data and Safety Monitoring Policy was published, study designs and monitoring practices have evolved, creating the need for more efficient and flexible practices to monitor data for all clinical research. NIH plans to modernize the Data and Safety Monitoring Policy starting with gathering input from the public, experts in the field, and the research community.

NIH Videocast

https://videocast.nih.gov

Draft Agenda

Draft Agenda

Meeting Flyer

Meeting Flyer

Public Comments

All types of clinical research studies can – and should – have a plan for monitoring data and safety. These studies include a broad range of clinical research studies, such as observational studies, behavioral and social science research, implementation science, and clinical trials of drugs and devices.

  • Data and safety monitoring plans identify the approach and procedures for monitoring the quality and scientific reliability of the data, and the safety of participants.
  • Plans include procedures for evaluating and reporting on the data and safety of the study.
  • Plans identify the appropriate level of monitoring for the study and describe how that monitoring will be conducted.
  • Monitoring can range from the principal investigator only to including an independent monitor(s) or committee, like a Data and Safety Monitoring Board (DSMB).

NIH welcomes any comments on modernizing the Data and Safety Monitoring (DSM) Policy. We accept any comments, but we are specifically interested in hearing individual opinions on the following topics:

  • Study characteristics that should be considered when evaluating what an appropriate monitoring approach, plan, or level of monitoring is for the study. For example, this could include the study design, types of outcomes, data privacy and security, US or global regulatory structure, number of sites, and quantity and types of data.
  • Key components of an effective data and safety monitoring plan; considering data, safety, scientific integrity, protocol adherence, and study continuation.
  • Types of research that should be covered under the modernized DSM policy. Key categories are 1) all clinical research (including clinical trials and non-clinical trials) and 2) all research involving humans, including identifiable private information or specimens (i.e., secondary research involving de-identified private information or biospecimens).
  • Guidance, templates, or educational material that would help the research community 1) understand data and safety monitoring principles, 2) develop effective data and safety monitoring approaches and plans, and 3) implement data and safety monitoring rigorously and to the highest ethical standards.

Registration

Registration for this event is now closed.

Your Voice Matters: Help Shape a New NIH Policy on Summary Level Study Results

NIH is undertaking a comprehensive policy development process that will require researchers and institutions to responsibly share summary level study results to research participants in plain language for all NIH-supported clinical research. This webinar, co-hosted by the Multi-Regional Clinical Trial Center of Brigham and Women’s Hospital and Harvard, is an opportunity for stakeholders to provide feedback to inform the development of that policy.

NIH Videocast

https://videocast.nih.gov

Draft Agenda

Draft Agenda

Meeting Materials

Introductory Slides

Lyric Jorgenson, PhD

Associate Director for Science Policy, National Institutes of Health

Sharing Summary Level Study Results with Participants: Current Landscape

Barbara Bierer, MD

Professor of Medicine, Harvard Medical School

Faculty Director, Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard

Public Comments

NIH encourages any interested individual to sign up to provide oral comments during the listening session.  All comments offered at the listening session are welcome and will be considered. Feedback on the following topics is particularly encouraged.   

What to include in summary level study results shared with participants. Specifically:  

  • Elements and information that should be expected to be included in summary level study results shared with participants
  • Situations when not sharing summary level study results with participants may be justifiable
  • Strategies for generating plain language summaries, including the use of AI tools

How to share summary level study results with participants. Specifically:

  • Best practices for participant engagement to ensure that results are returned in meaningful ways and participants know what to expect
  • Acceptable and preferred methods for sharing and receiving summary level results
  • Potential costs related to generating and sharing summary level results
  • Additional considerations related to ensuring results are returned responsibly

When to share summary level study results with participants. Specifically:

  • Timing of sharing summary level study results (during or after the study)

Virtual Meeting and Listening Session on USG Oversight Framework for Research Involving Enhanced Potential Pandemic Pathogens

NIH will hold a virtual meeting and listening session to engage stakeholders and gather feedback on the current U.S. Government oversight framework for research involving enhanced potential pandemic pathogens. 

Specifically, NIH is interested in hearing from a wide range of stakeholders on the scope of the framework, strategies for minimizing potential biosafety and biosecurity risks, considerations for supporting international ePPP research and how to balance security with public transparency. This meeting and listening session will also help inform the deliberations and policy recommendations of the NSABB related to its current charge.  Time will also be on the agenda for members of the public to provide comments at the meeting.

Webcast

https://videocast.nih.gov/watch=45230

Agenda

Meeting and Virtual Listening Session Agenda

Background Materials

Public Comments

National Science Advisory Board for Biosecurity (NSABB) Meeting

Webcasts

Agenda

Meeting Minutes

Slides

Additional Materials

For accessibility assistance with these files, please contact: [email protected].